Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afamelanotide Impact on UV-Induced DNA Damage and Repair in Healthy Volunteers
2023-505907-21-00Phase 2Authorised
- Sponsor
- Clinuvel Pharmaceuticals
- Start
- Feb 2024
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, single-arm trial of Afamelanotide, sponsored by Clinuvel Pharmaceuticals. Primary endpoint: Change in ultraviolet radiation-induced DNA photoproducts in skin. Planned start Feb 2024; status: authorised.
02
Drugs
Afamelanotide
Beyond the preview
Go deeper on 2023-505907-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505907-21-00.